# ScoreItem: Testosterona Livre - Mulheres P√≥s-Menopausa

**ID:** `c77cedd3-2800-7abb-b210-e6c71ff27988`
**FullName:** Testosterona Livre - Mulheres P√≥s-Menopausa (Exames - Laboratoriais)
**Unit:** pg/mL
**Gender:** female
**Post-Menopause:** true

**Preparation Metadata:**
- Quality Grade: **EXCELLENT**
- Total Chunks: 30 de 11 artigos
- Avg Similarity: 0.706

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `c77cedd3-2800-7abb-b210-e6c71ff27988`.**

```json
{
  "score_item_id": "c77cedd3-2800-7abb-b210-e6c71ff27988",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** Testosterona Livre - Mulheres P√≥s-Menopausa (Exames - Laboratoriais)
**Unidade:** pg/mL
**G√™nero:** female

**30 chunks de 11 artigos (avg similarity: 0.706)**

### Chunk 1/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** results | **Similarity:** 0.758

antoroN.Androgensandfemalesexualfunctionanddysfunction‚ÄîFindingsfromthefourthinternationalconsultationofsexualmedicine.JSexMed.2016;13.48.ShifrenJL,BraunsteinGD,SimonJA,CassonPR,BusterJE,RedmondGP,etal.Transdermaltestosteronetreatmentinwomenwithimpairedsexualfunction
afteroophorectomy.NEnglJMed.2000;343:682‚Äì8.https://doi.org/10.1056/NEJM200009073431002.49.BusterJE,KingsbergSA,BuchA,RodenbergCA,WekselmanK.Testosteronepatchforlowsexualdesireinsurgicallymenopausalwomen:arandomizedtrial.Obstet
Gynecol.2005;105:944‚Äì52.https://doi.org/10.1097/01.AOG.0000158103.27672.0d50.DavisSR,MoreauM,KrollR,BouchardC,PanayN,GassM,etal.APHRODITEStudyTeam.Testosteroneforlowlibidoinpostmenopausalwomennottakingestro-
gen.NEnglJMed.2008;359:2005‚Äì17.https://doi.org/10.1056/NEJMoa0707302.51.PanayN,Al-AzzawiF,BouchardC,DavisSR,EdenJ,LodhiI,etal.TestosteronetreatmentofHSDDinnaturallymenopausalwomen:theADOREstudy.Climac-
teric.2010;13:121‚Äì31.https://doi.org/10.3109/13697131003675922.52.SimonJ,BraunsteinG,N

---

### Chunk 2/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** results | **Similarity:** 0.731

BouchardC,DavisSR,EdenJ,LodhiI,etal.TestosteronetreatmentofHSDDinnaturallymenopausalwomen:theADOREstudy.Climac-
teric.2010;13:121‚Äì31.https://doi.org/10.3109/13697131003675922.52.SimonJ,BraunsteinG,NachtigallL,UtianW,KatzM,MillerS,etal.Testosteronepatchincreasessexualactivityanddesireinsurgicallymenopausalwomenwith
hypoactivesexualdesiredisorder.JClinEndocrinolMetab.2005;90:5226‚Äì33.https://doi.org/10.1210/jc.2004-1747.53.ShifrenJL,DavisSR,MoreauM,WaldbaumA,BouchardC,DeRogatisL,etal.Testosteronepatchforthetreatmentofhypoactivesexualdesiredisorderin
naturallymenopausalwomen:resultsfromtheINTIMATENM1Study.Meno-
pause.2006;13:770‚Äì9.https://doi.org/10.1097/01.gme.0000243567.32828.99.Erratumin:Menopause.2007Jan-Feb;14(1):157.PMID:1693224054.HuangG,BasariaS,TravisonTG,HoMH,DavdaM,MazerNA,etal.Testosteronedose-responserelationshipsinhysterectomizedwomenwithorwithout
oophorectomy:effectsonsexualfunction,bodycomposition,muscleperfor-
manceandphysicalfunctioninarandomizedtrial.Menopause.2014

---

### Chunk 3/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.720

dose dehydroepiandrosterone affects
behavior in hypopituitary androgen-deficient women: a placebocontrolled trial. J Clin
Endocrinol Metab 2002;87:2046
144. van Thiel SW, Romijn JA, Pereira AM, et al. Effects of dehydroepiandrostenedione,
superimposed on growth hormone substitution, on quality of life and insulin-like growth factor
I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-
over trial. J Clin Endocrinol Metab 2005;90:3295‚Äì303
145. Lovas K, Gebre-Medhin G, Trovik T, et al. Replacement of dehydroepiandrosterone in
adrenal failure: no benefit for subjective health status and sexuality in a 9-month randomized
parallel group clinical trial. J Clin Endocrinol Metab 2003;88:1112‚Äì8
146. Avis NE, Brockwell S, Randolph Jr JF, et al. Longitudinal changes in sexual functioning
as women transition through menopause: results from the Study of Women‚Äôs Health Across
the Nation. Menopause 2009;16:442‚Äì52
147.

---

### Chunk 4/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 04 (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.720

tosterona livre‚Äù calculada do soro como decisor; incluir, quando indicado, painel salivar (testosterona, DHT, estradiol; progesterona no D22‚ÄìD24) juntamente com sangue total e SHBG.
- [ ] 5. Implementar triagem de fatores ambientais/ocupacionais que elevem temperatura escrotal (vestimenta apertada, longos per√≠odos sentado, dormir de cueca, ambientes quentes) e orientar medidas corretivas.
- [ ] 6. Estabelecer protocolo para avalia√ß√£o p√≥s-ciclo de testosterona (end√≥gena/ex√≥gena), reconhecendo per√≠odos de LH/FSH inibidos e evitando interpreta√ß√µes equivocadas de queda transit√≥ria.
- [ ] 7. Preparar leitura dos estudos recomendados sobre obesidade e hipogonadismo, bari√°trica e revers√£o hormonal, e rela√ß√µes entre obesidade e andropausa, para discuss√£o na pr√≥xima aula.
- [ ] 8. Educar equipes cl√≠nicas sobre a inadequa√ß√£o de prescrever inibidores de PDE5 (Viagra/Cialis) sem avalia√ß√£o hormonal quando h√° suspeita de disfun√ß√£o androg√™nica.
- [ ] 9.

---

### Chunk 5/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 03 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.720

, estradiol (cr√≠tico para desejo), diidrotestosterona (DHT), ovula√ß√£o, atra√ß√£o f√≠sica, sono; contraceptivos e ins√¥nia alteram fortemente.
* Exames e confiabilidade
   - Exames de testosterona para mulheres s√£o pouco confi√°veis; deve-se priorizar a cl√≠nica e considerar teste terap√™utico, monitorando exames para evitar excesso. Mesmo com testosterona ‚Äúalta‚Äù em laborat√≥rio, receptores hormonais podem variar.
   - Anticoncepcionais combinados elevam SHBG, reduzem testosterona livre e atrapalham resposta √† reposi√ß√£o. Com anticoncepcional, a testosterona administrada tende a ser sequestrada pelo SHBG, reduzindo efetividade.
* Manejo pr√°tico
   - Considerar retirar p√≠lula quando poss√≠vel: pode ocorrer queda de cabelo, acne e ‚Äúdesbagun√ßa‚Äù hormonal por cerca de 3 meses; com sa√∫de e suporte (suplementa√ß√£o, alimenta√ß√£o, exerc√≠cio, modula√ß√£o do eixo HPA, mitoc√¥ndrias), tende a estabilizar.

---

### Chunk 6/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 03 (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.718

vida.
   - Em materiais did√°ticos do Dr. Merwin/Morgan Taylor, resultados foram apresentados como sem aumento de risco (‚Äúharmful zero‚Äù) e com benef√≠cios gerais na reposi√ß√£o quando bem indicada.
* Preven√ß√£o vs tratamento agudo
   - A testosterona n√£o ‚Äúsalva‚Äù no evento agudo (infarto), mas pode ter papel preventivo ao melhorar fatores de risco e estado geral (ex.: composi√ß√£o corporal, energia, bem-estar).
### 4. Avalia√ß√£o cl√≠nica e question√°rios
* Ferramentas de triagem
   - Question√°rios citados: St. Louis University (ADAM), AMS, MMAS, HRS. Podem ser baixados, mas o instrutor considera desnecess√°rios como √∫nico crit√©rio, devido √† ampla inespecificidade dos sintomas.
* Sintomas e sinais de baixa testosterona
   - Homens: irritabilidade, fadiga, baixa libido, diminui√ß√£o de pelos nas pernas, depress√£o, sarcopenia, aumento de gordura (principalmente abdominal), ins√¥nia, disfun√ß√£o er√©til.

---

### Chunk 7/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** other | **Similarity:** 0.716

r-
net].SouthDartmouth(MA):MDText.com,Inc.;2000.Availablefrom:https://www.ncbi.nlm.nih.gov/books/NBK279000/14.GuayA,MunarrizR,JacobsonJ,TalakoubL,TraishA,QuirkF,etal.Serumandrogenlevelsinhealthypremenopausalwomenwithandwithoutsexualdysfunction:partA.Serumandrogenlevelsinwomenaged20‚Äì49yearswithnocomplaintsofsexualdysfunction.IntJImpotRes.2004;16:112‚Äì20.15.BurgerHG,DudleyEC,CuiJ,DennersteinL,HopperJL.Aprospectivelongitudinalstudyofserumtestosterone,dehydroepiandrosteronesulfate,andsexhormone-
bindingglobulinlevelsthroughthemenopausetransition.JClinEndocrinol
Metab.2000;85:2832‚Äì8.16.JuddHL,LucasWE,YenSSC.Effectofoophorectomyoncirculatingtestosteroneandandrostenedionelevelsinpatientswithendometrialcancer.AmJObstetGynecol.1974;118:793‚Äì8.17.DavisSR,McCloudP,StraussBJG,BurgerH.Testosteroneenhancesestradiol‚Äôseffectsonpostmenopausalbonedensityandsexuality.Maturitas.1995;21:227‚Äì36.18.DavisSR,BurgerHG.Therationaleforphysiologicaltestosteronereplacementinwomen.Bailliere‚ÄôsClinEndocrin

---

### Chunk 8/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** discussion | **Similarity:** 0.715

.1210/jcem.83.11.5280.65.DavisSR,BraunsteinGD.Efcacyandsafetyoftestosteroneinthemanagementofhypoactivesexualdesiredisorderinpostmenopausalwomen.JSexMed.
2012;9:1134‚Äì48.https://doi.org/10.1111/j.1743-6109.2011.02634.x.66.KischeH,GrossS,WallaschofskiH,V√∂lzkeH,D√∂rrM,NauckM,etal.Clinicalcorrelatesofsexhormonesinwomen:ThestudyofhealthinPomerania.Meta-
bolism.2016;65:1286‚Äì96.https://doi.org/10.1016/j.metabol.2016.05.011.67.MukaT,NanoJ,JaspersL,MeunC,BramerWM,HofmanA,etal.Associationsofsteroidsexhormonesandsexhormone-bindingglobulinwiththeriskoftype2
diabetesinwomen:apopulation-basedcohortstudyandmeta-analysis.Dia-betes.2017;66:577‚Äì86.https://doi.org/10.2337/db16-0473.68.KennedyRG,DaviesT,Al-AzzawiF.Sexualinterestinpostmenopausalwomenisrelatedto5alpha-reductaseactivity.HumReprod.1997;12:209‚Äì13.https://doi.org/10.1093/humrep/12.2.209.69.WiermanME,ArltW,BassonR,DavisSR,MillerKK,MuradMH,etal.Androgentherapyinwomen:areappraisal:anEndocrineSocietyclinicalpracticeguideline.

---

### Chunk 9/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 09 (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.714

suplemento mais prescrito, mas com resultados inconsistentes para o aumento de testosterona.
     - Revis√µes sistem√°ticas s√£o categ√≥ricas em afirmar que n√£o funciona para elevar a testosterona.
     - No entanto, pode melhorar a libido e a disposi√ß√£o, especialmente em mulheres, independentemente dos n√≠veis de testosterona.
     - O palestrante adverte que seu uso pode desregular outros horm√¥nios, como o aumento excessivo de DHT em algumas mulheres, tornando seu efeito imprevis√≠vel.
* **Terapias M√©dicas e Estrat√©gia de Tratamento**
   - **Abordagens n√£o medicamentosas (Prioridade 1):** Dieta, exerc√≠cio, perda de peso, melhora do sono, redu√ß√£o do estresse e reparo de varicocele (se presente) s√£o fundamentais e devem ser sempre orientadas.
   - **Indica√ß√µes M√©dicas (Abordagens Sequenciais):**
     - **HCG (Gonadotrofina Cori√¥nica Humana):** √â um an√°logo do LH que estimula diretamente os test√≠culos a produzirem testosterona.

---

### Chunk 10/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 03 (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.714

integrar faixas de refer√™ncia e propor√ß√µes hormonais (testosterona, DHT, estradiol), al√©m de limiares pr√°ticos.**
- Laborat√≥rios reportam faixas distintas de testosterona total: 200‚Äì800 ng/dL como inferior‚Äìsuperior t√≠pico; alguns usam 1200 como superior; indiv√≠duos podem atingir ‚Äúmil e tanto‚Äù, ilustrando variabilidade e limita√ß√£o de olhar um √∫nico valor atual.
- Limiar pr√°tico: acima de 500‚Äì600 ng/dL, queixas por baixa testosterona s√£o raras; em 300 ng/dL, considerar defici√™ncia, interpretando junto com DHT e estradiol.
- Exemplos de DHT: 500‚Äì600 (alto, sugere que n√£o √© falta de testosterona) e 400 (pode coexistir com testosterona baixa); estradiol: 20‚Äì25 (proporcional em testosterona baixa) e 20 (tudo certo quando proporcional), refor√ßando an√°lise de equil√≠brio hormonal.

---

### Chunk 11/30
**Article:** Testosterone in women‚Äîthe clinical significance (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.713

he Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the 
assessment of female sexual function. J Sex Marital Ther 2000; 
26: 191‚Äì208.17 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American 
Psychiatric Press, 1994.18 Elraiyah T, Sonbol MB, Wang Z, et al. Clinical review: The beneÔ¨Å ts and harms of systemic testosterone therapy in postmenopausal 
women with normal adrenal function: a systematic review and 
meta-analysis. J Clin Endocrinol Metab 2014; 99: 3543‚Äì50.19 Davis SR, Moreau M, Kroll R, et al, and the APHRODITE Study Team. Testosterone for low libido in postmenopausal women not 
taking estrogen. N Engl J Med 2008; 359: 2005‚Äì17.20 Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 
2005; 4: CD004509.21 Baldassarre M, Perrone AM, Giannone FA, et al.

---

### Chunk 12/30
**Article:** Psiquiatria Metab√≥lica Funcional Integrativa AULA 19 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.711

na ligadora de horm√¥nios sexuais), que se liga com alta afinidade √† testosterona, reduzindo sua biodisponibilidade.
   - H√° menor s√≠ntese de testosterona ovariana por bloqueio de LH e poss√≠vel redu√ß√£o de androg√™nese adrenal; a produ√ß√£o feminina j√° √© limitada, agravada pela SHBG elevada.
* Medi√ß√£o e terap√™utica de testosterona em mulheres
   - Teste sangu√≠neo de testosterona feminina √© pouco fidedigno devido aos n√≠veis muito baixos; avalia√ß√£o salivar √© considerada mais precisa, assim como cortisol salivar.
   - Prescri√ß√£o: em mulheres sem anticoncepcionais e com sintomas (fadiga, baixa libido), podem-se testar baixas doses de creme de testosterona com avalia√ß√£o de resposta; n√£o esperar ganho de massa magra com creme.
   - Em usu√°rias de anticoncepcionais, recuperar testosterona livre √© dif√≠cil; seriam necess√°rias ‚Äúmega doses‚Äù, o que n√£o vale pela captura pela SHBG.

---

### Chunk 13/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 04 (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.710

itos.
- Queda de cabelo acentuada.
- TPM muito intensa em mulheres.
## Objetivo:
Aula, n√£o consulta. Achados objetivos/patol√≥gicos gerais:
- Testosterona em homens diminui com a idade; n√≠veis <400 ng/dL s√£o considerados baixos.
- Baixa testosterona associada a maior ocorr√™ncia de obesidade, hipertens√£o, hiperlipidemia, alergias e diabetes.
- Alta preval√™ncia de hipogonadismo hipogonadotr√≥fico (falta de comando central) em homens obesos.
- Obesidade aumenta atividade da aromatase, resist√™ncia √† insulina e apneia do sono, levando a hipogonadismo hipotal√¢mico.
- Obesidade pode elevar a temperatura escrotal, piorar produ√ß√£o de testosterona e levar a oligospermia/azoospermia.
- Exames de sangue para horm√¥nios livres (ex.: testosterona livre) s√£o imprecisos no Brasil, pois laborat√≥rios calculam em vez de medir diretamente; ~80% dos horm√¥nios livres aderem √†s hem√°cias e s√£o removidos na centrifuga√ß√£o.

---

### Chunk 14/30
**Article:** Terapia de Reposi√ß√£o Hormonal Feminina III (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.707

enos) e toxinas ambientais.
### 4. Reposi√ß√£o de Testosterona em Mulheres
*   **Indica√ß√µes e Benef√≠cios:**
    - A principal indica√ß√£o √© a desordem de hipoatividade sexual (baixo desejo sexual).
    - Melhora a massa √≥ssea e muscular, o desejo sexual e diminui escores de depress√£o, especialmente em mulheres com defici√™ncia severa.
    - Ajuda a prevenir a fragilidade associada ao envelhecimento.
*   **Seguran√ßa:**
    - A reposi√ß√£o com testosterona n√£o oral em n√≠veis fisiol√≥gicos n√£o demonstrou aumentar o risco de cancro da mama, com alguns estudos sugerindo at√© um efeito protetor.
### 5. Recomenda√ß√µes de Tratamento e Abordagem Hol√≠stica
*   **Terapia Ideal:**
    - A combina√ß√£o de **17-beta-estradiol transd√©rmico** com **progesterona natural micronizada oral** √© considerada a mais segura e ben√©fica.
*   **Dosagens e Vias:**
    - **Estradiol:** Gel (0,3-2,5 mg) ou adesivos (50-100 mcg). A dose √© ajustada clinicamente.

---

### Chunk 15/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** results | **Similarity:** 0.704

tosteroneisunboundfromalbuminorSHBG,itcanbindtotheARasfreetestosteroneorbeconvertedtothemorepotentDHTwhichhasastrongerafnitytotheAR[9].Onceboundtothereceptor,itistranslocatedintothenucleusforgenetranscription[12].Thisresultsingeneactivationofvariouscellularactivityincludingmetabolism,cognition,andsexualfunction[13].Aswomenage,thereisanoveralldecreaseinandrogenproductionduetoage-relateddeclineofovarianandadrenalfunction,whichoccursduringmenopause[14].ThesteadydeclineoftestosteronebeginsafterearlyreproductiveyearswithasmallincreaseduringmenopauseduetothedecreaseinSHGB[15].Incomparison,womenwhoundergosurgicalmenopausehavea
markedandpermanentdecreaseintestosteroneproduction[16].Theirlevelsareupto50%lowerthanwomenwhoundergomenopausenaturally[16].Androgenshavebeendemonstratedtoplayaroleinsexualmotivationinwomen,includingbutnotlimitedtoexhibitingsexualinterest,initiatingsexualactivity,andrespondingtosexualstimula-tion[17‚Äì22].Asaresult,decreasedtestosteronelevelshavebeenhypothesizedtobeanim

---

### Chunk 16/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** results | **Similarity:** 0.703

unctionandhyperlipidemiaarecontraindicationsforTRT.Totaltestosteroneshouldbeevaluated3‚Äì6weeksafterinitiationofTRTandrepeatedwithin6weeksanytimethereisadoseadjustmentduringtitrationtophysiologiclevelsasdeterminedbythepatient‚Äôslaboratory[24,27,29].Patientsshouldbecounseledthatitwilltakeupto12weekstoseemaximalresultsbutto
expecttoseeimprovementinsymptoms6‚Äì8weeksafterinitiationoftreatmentwithsomewomenseeingresultsasearlyas4weeks[65].Qualitativeandsubjectivetreatmentresponsesshouldbemonitored,suchasanincreaseinsexualdesire,
improvementinqualityoflife,anddecreaseinpersonaldistress[59].Self-reportedvalidatedinstruments(e.g.,FSFI,FSDS)canbeadministeredasasupplementalandobjectivemeanstoassess
treatmentoutcomes[36,39].Patientsshouldalsobeassessedforsideeffectsincludingacne,hirsutism,andandrogenicalopecia.Itisrecommendedthattotaltestosteronedoesnotmarkedlyexceedtheupperlimitofthereferencerangetodecreasethe
riskofadrenergicsideeffects[24].Thesesideeffectscanalsooccurwithnormalserumlevelsofto

---

### Chunk 17/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 11 (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.703

ticas, t√©cnicas de aplica√ß√£o (IM vs. SC em gordura) e considera√ß√µes sobre fertilidade (inibi√ß√£o do eixo HPT), PSA e sa√∫de prost√°tica. Paralelamente, aborda-se modula√ß√£o de estr√≥genos com indol-3-carbinol e DIM baseados em achados do DUT test, testosterona em mulheres para desejo sexual hipoativo (doses baixas e cautelas), uso criterioso de gestrinona (prefer√™ncia por creme vaginal antes de implante), limites profissionais e necessidade de co-manejo com urologistas. Diferenciam-se reposi√ß√£o hormonal de uso anabolizante, destacando-se riscos, √©tica, contamina√ß√£o de suplementos e a primazia da correla√ß√£o cl√≠nica sobre ‚Äúvalores ideais‚Äù fixos. A grava√ß√£o foi analisada em 2025-11-21; refer√™ncias temporais foram interpretadas literalmente.
## üîñ Pontos de Conhecimento
### 1. Modalidades injet√°veis de TRT e aceita√ß√£o cl√≠nica
- Undecilato de testosterona (Nebido e gen√©ricos)
  - √âster de libera√ß√£o lenta; aplica√ß√£o trimestral na bula.

---

### Chunk 18/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.698

%CI1.13‚Äì4.50;P=0.02forcardiovascularhospitalization)(TableS1).Similarresultswereobtainedafterexcluding(n=8)patientswithLVEFbetween40and45%(Table2).DiscussionThemainndingsofthecurrentstudyarethat(1)TDishighlyprevalentamongwomenwithHFrEF,around
one-third;(2)whenpresent,TDshapesaclustercharacter-izedbyreducedexercisecapacity,abnormalrightventricular-arterialcouplingandimpairedrenalfunction;(3)
TDhasasignicantimpactonmorbidityandmortalityoffemalepatientsaffectedbyHFrEFbeinganindependent
Testosteronedeciencyinwomenwithheartfailure3ESCHeartFailure(2022)DOI:10.1002/ehf2.14117
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

predictorofall-causemortalityandcardiovascularhospitali-zation.Tothebesttoourknowledge,thisreportistherstaddressingtheimpactofTDinwomenaffectedbyHFrEF.Impactoftestosteronedeciencyonclinicalstatus,morbidity,andmortalityoffemaleHFrEFTheevidenceofapositiveeffectplayedbytestosteroneoncardi

---

### Chunk 19/30
**Article:** Testosterone in women‚Äîthe clinical significance (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.695

6 months. In this study, women given testosterone had 
signiÔ¨Å cant improvements in the 6-min walk test, oxygen consumption, and insulin resistance compared with 
those given placebo, and better performance in each of 
these tests is associated with better prognosis for 
congestive cardiac failure.54 This study does not suggest that women with congestive cardiac failure should be 
given testosterone but rather supports the need for better 
understanding of the role of testosterone in the 
pathogenesis of cardiovascular disease in women.Testosterone and cognitionEvidence from basic and clinical studies suggests that sex 
steroids a ect cognitive decline and progression to dementia in women. Findings from basic studies55,56 have shown that oestradiol and testosterone are neuroprotective 
Panel: Taking sex hormone-binding globulin into accountTestosterone in women is most often considered in the context of excess concentrations and polycystic ovary syndrome.

---

### Chunk 20/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 11 (2024)
**Journal:** Pos Graduacao MFI
**Section:** introduction | **Similarity:** 0.694

0 mg/dia para ajustar vias de estronas conforme DUT e quadro cl√≠nico.
  - Evitar dogmas de ‚Äúvalores ideais‚Äù fixos; tratar a pessoa, n√£o apenas n√∫meros.
### 9. Testosterona em mulheres: indica√ß√µes e cautelas
- Indica√ß√£o: transtorno de desejo sexual hipoativo; preferir creme.
- Avaliar contexto multifatorial de libido (dopamina, ocitocina, sono, estresse, rela√ß√£o).
- Doses: ‚â§5 mg/dia; doses altas elevam risco de acne, hirsutismo, queda de cabelo.
- Benef√≠cios poss√≠veis em fun√ß√£o cardiometab√≥lica e humor; evitar expectativas exageradas e vi√©s de placebo.
- N√£o abordar derivados anabolizantes femininos no escopo do curso.
### 10. Gestrinona: uso cl√≠nico e √©tica
- Indica√ß√µes: endometriose, predomin√¢ncia estrog√™nica; pode ter apelo est√©tico.
- Preferir teste com creme vaginal (2‚Äì5 mg, 3x/semana √† noite) por ‚â•1 m√™s antes de implante.
- Monitorar SHBG, HDL e efeitos androg√™nicos; evitar associa√ß√£o imediata com testosterona.

---

### Chunk 21/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** methods | **Similarity:** 0.694

https://doi.org/10.1111/j.1743-6109.2007.00672.x.40.ClaytonAH,GoldmeierD,NappiRE,WunderlichG,Lewis-D'AgostinoDJ,PykeR.Validationofthesexualinterestanddesireinventory-femaleinhypoactivesexual
desiredisorder.JSexMed.2010;7:3918‚Äì28.https://doi.org/10.1111/j.1743-6109.2010.02016.x.41.GoebelsmannU,ArceJJ,ThorneycroftIH,MishellDRJr.SerumtestosteroneconcentrationsinwomenthroughoutthemenstrualcycleandfollowingHCG
administration.AmJObstetGynecol.1974;119:445‚Äì52.https://doi.org/10.1016/0002-9378(74)90199-9.42.WangC,CatlinDH,DemersLM,StarcevicB,SwerdloffRS.Measurementoftotalserumtestosteroneinadultmen:comparisonofcurrentlaboratorymethods
versusliquidchromatography-tandemmassspectrometry.JClinEndocrinol
Metab.2004;89:534‚Äì43.43.MillerKK,RosnerW,LeeH,HierJ,SesmiloG,SchoenfeldD,etal.Measurementoffreetestosteroneinnormalwomenandwomenwithandrogendeciency:comparisonofmethods.JClinEndocrinolMetab.2004;89:525‚Äì33.44.ViswanathanCT,BansalS,BoothB,DeStefanoAJ,RoseMJ,SailstadJ,etal.Quantitativebioanal

---

### Chunk 22/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** other | **Similarity:** 0.693

[40],theFemaleSexualDistressScale[39],andtheDecreasedSexualDesireScreener[37].Acomprehensivephysicalexamshouldbeperformedincludingadetailedgenitalexam,examiningforsignsofhypogonadismlike
decreasedclitoralsize,labialresorption,vestibularerythemaorpallor,degreeofvaginalatrophy,andelevatedvaginalpH.Acompletehormonalpanelshouldbeobtainedincludingtotaltestosterone,free
testosterone,estradiol,andSHBG.Estradiol,prolactin,andthyroid-stimulatinghormonecanalsobeorderedifindicated[27].Duetothelowlevelsoftestosteronelevelsinwomencomparedtomen,
therearelimitationsinprecisionintheavailableassaysusedto
measuretestosterone.Radioimmunoassay(RIA)isthemostusedtechniquetomeasuretotaltestosteroneinwomen[41].Thisassayisoftenunreliableinwomen,asithasnotbeenstandardizedto
measuretestosteronelevelsinwomennationallyorinternationally
[42,43].Ifavailable,liquidchromatography(LC)/gaschromatography(GC)andLC-tandemmassspectrometry(MS/MS)assaysshouldbeusedinsteadtomeasuretotaltestosterone,asitprovidesamore
reliablean

---

### Chunk 23/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** other | **Similarity:** 0.693

eenhancesestradiol‚Äôseffectsonpostmenopausalbonedensityandsexuality.Maturitas.1995;21:227‚Äì36.18.DavisSR,BurgerHG.Therationaleforphysiologicaltestosteronereplacementinwomen.Bailliere‚ÄôsClinEndocrinolMetab.1998;12:391‚Äì405.19.GreenblattRB,MortaraF,TorpinR.Sexuallibidointhefemale.AmJObstetGynecol.1942;44:658‚Äì63.20.SherwinBB,GelfandMM.Theroleofandrogeninthemaintenanceofsexualfunctioninginoophorectomizedwomen.PsychosomMed.1987;49:397‚Äì409.https://doi.org/10.1097/00006842-198707000-00009.21.SherwinBB,GelfandMM,BrenderW.Androgenenhancessexualmotivationinfemales:aprospective,crossoverstudyofsexsteroidadministrationinthesur-gicalmenopause.PsychosomMed.1985;47:339‚Äì51.https://doi.org/10.1097/00006842-198507000-00004.22.RandolphJFJr,ZhengH,AvisNE,GreendaleGA,HarlowSD.Masturbationfre-quencyandsexualfunctiondomainsareassociatedwithserumreproductive
hormonelevelsacrossthemenopausaltransition.JClinEndocrinolMetab.

---

### Chunk 24/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** results | **Similarity:** 0.693

the300ggrouphadsignicantlygreaterSatisfyingSexualEvents(SSEs)over4weekswhencomparedtotheplacebogroup(episodesper4weeks:anincreaseof2.1
episodesvs.0.7,P<0.001).Thiseffect,however,wasnotseeninthepatientsrandomizedtothe150g/daygroup(1.2episodesvs.0.7,P=0.11).IntheADOREstudy,Panayetal.[51]foundsimilarresultsintheir2010placebo-controlled,double-blindtrial
conductedoversixmonths.272menopausalwomenwererandomizedtoeitherreceiveatransdermaltestosteronepatch(300g/d)oraplacebo.Theyfoundimprovementinlibido(P=0.0007),SSEs,(P=0.0089),andreducedpersonaldistress(P=0.0024)inthetestosteronegroupcomparedwithplacebo.Regardingcombinationtherapy,Simonetal.[52]foundthattestosteroneadministration(viaapatch)incombinationwith
estrogenimprovedlibidoandthefrequency.Thismulticenter
studyof562womenwhounderwentsurgicallyinducedmenopauseshowedatotalsatisfyingsexualactivityfrom2.82to4.92episodesper4weeksinthetreatmentgroupincomparison
totheplacebo,2.94‚Äì3.92episodes(P=0.0003)per4weeksmeasuredbysexualactivitylog(S

---

### Chunk 25/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 09 (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.691

de v√°rios suplementos e fitoter√°picos, como √°cido D-asp√°rtico, ashwagandha, mucuna, Long Jack, fenogrego e tribulus, questionando seus resultados na pr√°tica cl√≠nica. Por fim, introduz as terapias m√©dicas, incluindo o uso de HCG, bloqueadores de estradiol e moduladores seletivos do receptor estrog√™nico (SERMs) como o clomifeno, estabelecendo uma hierarquia de tratamento que prioriza mudan√ßas no estilo de vida.
## üîñ Pontos de Conhecimento
### 1. Consenso sobre a Terapia de Testosterona
* **Significado Cl√≠nico da Defici√™ncia de Testosterona**
   - √â definida como uma condi√ß√£o m√©dica clinicamente significativa e bem estabelecida.
   - Afeta negativamente a sexualidade masculina, a reprodu√ß√£o, a sa√∫de geral e a qualidade de vida.
   - Os sinais e sintomas ocorrem devido a baixos n√≠veis de testosterona e podem melhorar com o tratamento, independentemente da causa subjacente ser identificada.
   - √â considerada um problema de sa√∫de p√∫blica global.

---

### Chunk 26/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.689

Stanczyk FZ, Bairey Merz CN. DHEA-S levels and
cardiovascular disease mortality in postmenopausal women: Results from the National
Institutes of Health‚ÄìNational Heart, Lung, and Blood Institute (NHLBI)-sponsored Women‚Äôs
Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab 2010;95:4985‚Äì4992
204. Christiansen JJ, Andersen NH, S√∏rensen KE, Pedersen EM, Bennett P, Andersen M,
Christiansen JS, J√∏rgensen JO, Gravholt CH. Dehydroepiandrosterone substitution in
female adrenal failure: no impact on endothelial function and cardiovascular parameters
despite normalization of androgen status. Clin Endocrinol 2007;66:426‚Äì433
205. Panjari M, Bell RJ, Jane F, Adams J, Morrow C, Davis SR. The safety of 52 weeks of
oral DHEA therapy for postmenopausal women. Maturitas 2009;63:240‚Äì245
206. Cleary MP, Zisk JF. Anti-obesity effect of two different levels of
dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. Int J Obes
1986;10:193‚Äì204
207.

---

### Chunk 27/30
**Article:** Testosterone in women‚Äîthe clinical significance (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.688

double-blind, placebo-controlled study. 
J Clin Endocrinol Metab 2006; 91: 1683‚Äì90.80 Popat VB, Calis KA, Kalantaridou SN, et al. Bone mineral density in young women with primary ovarian insu  ciency: results of a 
three-year randomized controlled trial of physiological transdermal 
estradiol and testosterone replacement. 
J Clin Endocrinol Metab 2014; 99: 3418‚Äì26.81 Dobs AS, Nguyen T, Pace C, Roberts CP. Di erential e ects of oral estrogen versus oral estrogen-androgen replacement therapy on 
body composition in postmenopausal women. 
J Clin Endocrinol Metab 2002; 87: 1509‚Äì16.82 Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2: 133‚Äì40.83 Davis SR. Cardiovascular and cancer safety of testosterone in women. Curr Opin Endocrinol Diabetes Obes 2011; 18: 198‚Äì203.84 Peters AA, Buchanan G, Ricciardelli C, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast 
cancer.

---

### Chunk 28/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 11 (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.687

e vaginal (2‚Äì5 mg, 3x/semana √† noite) por ‚â•1 m√™s antes de implante.
- Monitorar SHBG, HDL e efeitos androg√™nicos; evitar associa√ß√£o imediata com testosterona.
- √âtica: evitar implantes caros sem teste pr√©vio; transpar√™ncia para ades√£o sustent√°vel.
- N√£o prescrever gestrinona para homens.
### 11. Reposi√ß√£o versus anaboliza√ß√£o e escolhas de √©steres
- Reposi√ß√£o visa estabilidade e sa√∫de; anaboliza√ß√£o busca ganhos r√°pidos com maior risco (aromatiza√ß√£o, reten√ß√£o, eritrocitose).
- Resultados extremos exigem esteroides cr√¥nicos; n√£o prometidos por TRT/cremes/implantes.
- Risco de contamina√ß√£o em suplementos ‚Äúnaturais‚Äù; suspeitar de resultados ‚Äúmilagrosos‚Äù.
- Durateston: √∫til em transforma√ß√£o, n√£o ideal para manuten√ß√£o de TRH de longo prazo por controle mais dif√≠cil.
### 12. Abordagem centrada no paciente
- Observa√ß√£o cl√≠nica acima de n√∫meros isolados; horm√¥nios s√£o din√¢micos.

---

### Chunk 29/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 03 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.687

Indica√ß√£o principal: transtorno do desejo sexual hipoativo, com suporte de revis√µes sistem√°ticas.
- Libido feminina √© multifatorial (ocitocina, dopamina, estradiol, DHT, ovula√ß√£o, atra√ß√£o, etc.).
- Exames de testosterona em mulheres s√£o pouco confi√°veis; diagn√≥stico cl√≠nico com exclus√£o de outras causas.
- Anticoncepcionais (p√≠lulas, DIU hormonal) elevam SHBG, reduzindo testosterona livre e a libido.
- Suspens√£o da p√≠lula pode causar efeitos tempor√°rios (queda de cabelo, acne) por ~3 meses; caminho para restaurar n√≠veis hormonais.
- Prescrever testosterona para mulheres em uso de anticoncepcional tem pouca efic√°cia.
> **Sugest√µes da IA**
> Clareza na complexidade da libido feminina e impacto dos anticoncepcionais. Sugest√£o: analogia do SHBG como ‚Äúesponjas que absorvem a testosterona dispon√≠vel‚Äù para facilitar compreens√£o. Orienta√ß√£o realista sobre adapta√ß√£o p√≥s-p√≠lula.
### 5.

---

### Chunk 30/30
**Article:** Association between Serum Total Testosterone Level and Bone Mineral Density in Middle-Aged Postmenopausal Women (2022)
**Journal:** International Journal of Endocrinology
**Section:** discussion | **Similarity:** 0.686

ethesameasforfemaleosteo-porosis?‚ÄùEuropeanJournalofEndocrinology,vol.183,no.3,pp.R75‚Äìr93,2020.[7]V.Rochira,‚ÄúLate-onsethypogonadism:bonehealth,‚ÄùAndrology,vol.8,no.6,pp.1539‚Äì1550,2020.[8]G.Corona,W.Vena,A.Pizzocaroetal.,‚ÄúTestosteronesupplementationandboneparameters:asystematicreviewandmeta-analysisstudy,‚ÄùJournalofEndocrinologicalInves-tigation,vol.45,no.5,pp.911‚Äì926,2022.[9]N.V.Mohamad,I.N.Soelaiman,andK.Y.Chin,‚ÄúAconcisereviewoftestosteroneandbonehealth,‚ÄùClinicalInterventionsinAging,vol.11,pp.1317‚Äì1324,2016.[10]D.Arpaci,F.Saglam,F.N.Cuhaci,D.Ozdemir,R.Ersoy,andB.Cakir,‚ÄúSerumtestosteronedoesnota3ectbonemineraldensityinpostmenopausalwomen,‚ÄùArchEndocrinolMetab,vol.59,no.4,pp.292‚Äì296,2015.[11]F.Wu,R.Ames,J.Clearwater,M.C.Evans,G.Gamble,andhI.R.Reid,‚ÄúProspective10-yearstudyofthedeterminantsofbonedensityandbonelossinnormalpostmenopausalwomen,includingthee3ectofhormonereplacemenththerapy,‚ÄùClinicalEndocrinology,vol.56,no.6,pp.703‚Äì711,2002.[12]D.H.Lee,S.H.Kong,H.

---

